Opinion

Video

Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

Experts discuss how bispecifics might be incorporated earlier in the lines of treatment for certain cancers, the steps that can be taken to improve access to bispecific therapies in underserved or rural community settings, and how partnerships among academic centers, manufacturers, and community practices can help accelerate the adoption of bispecific antibodies.

Video content above is prompted by the following:

  1. How might bispecifics be incorporated earlier in the lines of treatment for certain cancers?
  2. What steps can be taken to improve access to bispecific therapies in underserved or rural community settings?
  3. How can partnerships between academic centers, manufacturers, and community practices help accelerate the adoption of bispecific antibodies?
Related Videos
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
5 experts are featured in this series
4 experts are featured in this series.
3 experts are featured in this series.
4 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo